Vaccinex(VCNX)
ROCHESTER, NYBiotechnology
Focus: Vaccinex is a public biotech focused on monoclonal antibodies and targeted biological therapies, primarily in oncology, neurology, and immunology. The company is early-stage with minimal revenue ($570K in FY2024) and operates from Rochester, NY.
Profile data last refreshed 3h ago · AI intelligence enriched 3w ago
Funding Stage
PUBLIC
Open Jobs
0
About Vaccinex
AI assessmentNot HiringNo open roles listed right now. Follow Vaccinex to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Vaccinex's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
4/9 — Basic
Company HealthSolid
Pipeline
Early-stage
12 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Revenue
$570K
Pipeline & Clinical Trials
Anti-SEMA4D Monoclonal Antibody VX15/2503
Colon Carcinoma Metastatic in the LiverClinical Trials (1)
NCT03373188VX15/2503 and Immunotherapy in Resectable Pancreatic and Colorectal Cancer
Phase 1Help build intelligence for Vaccinex
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.